Susana S. Najera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Susana S. Najera has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Jordan L. Meier
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
16 shared publications - Amy James
Animal research Technical Support, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
15 shared publications - Baktiar O. Karim
Frederick National Laboratory for Cancer Research
15 shared publications - Brad Gouker
Molecular Histopathology Laboratory, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
15 shared publications - Carleen Klumpp-Thomas
National Center for Advancing Translational Sciences
15 shared publications - Catherine Wells
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
15 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 3 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Integrated computational and experimental immunoengineering of adeno-associated virus capsid T cell epitopes in mice
Adeno-associated virus (AAV) vectors are widely used in gene therapy, but their immunogenicity remains a significant challenge, limiting long-term efficacy and the feasibility of repeated administration. In this study, we combine computational prediction with experimental validation to engineer AAV9 capsids with reduced immunogenicity. To facilitate this, we developed the Epitope Modification and MHC Prediction (EMMP) pipeline, which systematically automates the evaluation of amino acid substitutions for their predicted effects on major histocompatibility complex (MHC) presentability. Using this pipeline, we modify a CD4⁺ T-cell epitope in the AAV9 capsid that is identified and characterized as a proof-of-concept. Two mutant variants, R312H and R312Q, are selected and evaluated for transduction efficiency in vitro and immune response modulation in vivo. Notably, R312Q shows a significant reduction in T-cell activation and anti-AAV9 antibody production, albeit with a slight reduction in transduction at low multiplicities of infection (MOI). These results demonstrate a rational approach for optimizing AAV vector design, with potential applications for improving the safety and efficacy of gene therapy.
- 3 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessIntegrated computational and experimental immunoengineering of adeno-associated virus capsid T cell epitopes in mice
Adeno-associated virus (AAV) vectors are widely used in gene therapy, but their immunogenicity remains a significant challenge, limiting long-term efficacy and the feasibility of repeated administration. In this study, we combine computational prediction with experimental validation to engineer AAV9 capsids with reduced immunogenicity. To facilitate this, we developed the Epitope Modification and MHC Prediction (EMMP) pipeline, which systematically automates the evaluation of amino acid substitutions for their predicted effects on major histocompatibility complex (MHC) presentability. Using this pipeline, we modify a CD4⁺ T-cell epitope in the AAV9 capsid that is identified and characterized as a proof-of-concept. Two mutant variants, R312H and R312Q, are selected and evaluated for transduction efficiency in vitro and immune response modulation in vivo. Notably, R312Q shows a significant reduction in T-cell activation and anti-AAV9 antibody production, albeit with a slight reduction in transduction at low multiplicities of infection (MOI). These results demonstrate a rational approach for optimizing AAV vector design, with potential applications for improving the safety and efficacy of gene therapy.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Structural figures of NAMPT inhibitors.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Structural figures of NAMPT inhibitors.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Time course study design for imaging and OT-82 treatment for hyperpolarized pyruvate 13C-MRSI. Post treatment MRSI was performed 5 hours post OT-82 dose #2.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Time course study design for imaging and OT-82 treatment for hyperpolarized pyruvate 13C-MRSI. Post treatment MRSI was performed 5 hours post OT-82 dose #2.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Cell proliferation rates of HLRCC cell lines treated with low and high concentrations of NAMPT inhibitors. A) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK262 after 96 hours. B) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK268 after 96 hours. C) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK365 after 96 hours.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Cell proliferation rates of HLRCC cell lines treated with low and high concentrations of NAMPT inhibitors. A) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK262 after 96 hours. B) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK268 after 96 hours. C) Effect of OT-82 at 0.8nM or 100nM (left) and GNE-618 at 8nM or 200nM (right) on cell proliferation of UOK365 after 96 hours.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
HLRCC spheroid characterization and OT-82 effect on 3D culture. A) UOK262 and (B) UOK365 spheroids plated at different cell densities (8000, 4000, and 2000 cells/well in triplicate) after 24h, showing different degrees of cell aggregation. Cell viability of UOK262 (C) and UOK365 (D) spheroids treated with GNE-618 (1 nM-500 nM) or OT-82 (0.2 nM-100 nM) assessed with Cell-Titer Glo 3D assay decreases in a dose dependent manner.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
HLRCC spheroid characterization and OT-82 effect on 3D culture. A) UOK262 and (B) UOK365 spheroids plated at different cell densities (8000, 4000, and 2000 cells/well in triplicate) after 24h, showing different degrees of cell aggregation. Cell viability of UOK262 (C) and UOK365 (D) spheroids treated with GNE-618 (1 nM-500 nM) or OT-82 (0.2 nM-100 nM) assessed with Cell-Titer Glo 3D assay decreases in a dose dependent manner.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
NAD+ and NADH analysis of UOK365 cells. Analysis of the relative levels of NAD+ and NADH and their ratio after 24 hour treatment of the UOK365 cell line model with a range of concentrations (0.5-100 nM) of either GNE-618 (A-B) or OT-82 (C-D). All levels were compared to cells treated with the amount of DMSO present in the highest concentration of the utilized drugs.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4. from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
NAD+ and NADH analysis of UOK365 cells. Analysis of the relative levels of NAD+ and NADH and their ratio after 24 hour treatment of the UOK365 cell line model with a range of concentrations (0.5-100 nM) of either GNE-618 (A-B) or OT-82 (C-D). All levels were compared to cells treated with the amount of DMSO present in the highest concentration of the utilized drugs.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
In vitro analysis of NAMPT inhibition on glycolysis in FH-deficient tumor cells. (A) Effects of the NAMPT inhibitor OT-82 (100 nM) on the extracellular acidification rate (ECAR) in the UOK262 and UOK365 HLRCC cell lines and the RPTEC normal cell line. (B) Representation of the different effects of OT-82 versus DMSO at time point 5 (designated by a star) after the injection of glucose in UOK262, UOK365, and RPTEC. 2-DG, 2-deoxyglucose.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
In vitro analysis of NAMPT inhibition on glycolysis in FH-deficient tumor cells. (A) Effects of the NAMPT inhibitor OT-82 (100 nM) on the extracellular acidification rate (ECAR) in the UOK262 and UOK365 HLRCC cell lines and the RPTEC normal cell line. (B) Representation of the different effects of OT-82 versus DMSO at time point 5 (designated by a star) after the injection of glucose in UOK262, UOK365, and RPTEC. 2-DG, 2-deoxyglucose.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Validation of MIPE hits in 96-well cytotoxicity screens and comparison of NAMPT inhibitor efficacy across a panel of HLRCC cell lines.
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Validation of MIPE hits in 96-well cytotoxicity screens and comparison of NAMPT inhibitor efficacy across a panel of HLRCC cell lines.
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
In vivo effects of NAMPT inhibitors in HLRCC xenograft models. Mean body weights are constant throughout the drug study for animals harboring UOK262 xenografts (A) and UOK365 xenografts (B; study shown in Figure 3A-B, n = 10 mice per arm, 95mg/kg OT-82 for 8 week duration). (C-D) H&E stained sections of retinas obtained from NSG mice treated with vehicle or 95mg/kg OT-82 for 5 days. (E-F) Caspase 3 stained sections of retinas obtained from NSG mice treated with vehicle or 95 mg/kg OT-82 for 5 days. Histological sections were evaluated for signs of retinal toxicity by a trained veterinary pathologist. No overt signs of retinal toxicity were observed (n=3 NSG mice).
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
In vivo effects of NAMPT inhibitors in HLRCC xenograft models. Mean body weights are constant throughout the drug study for animals harboring UOK262 xenografts (A) and UOK365 xenografts (B; study shown in Figure 3A-B, n = 10 mice per arm, 95mg/kg OT-82 for 8 week duration). (C-D) H&E stained sections of retinas obtained from NSG mice treated with vehicle or 95mg/kg OT-82 for 5 days. (E-F) Caspase 3 stained sections of retinas obtained from NSG mice treated with vehicle or 95 mg/kg OT-82 for 5 days. Histological sections were evaluated for signs of retinal toxicity by a trained veterinary pathologist. No overt signs of retinal toxicity were observed (n=3 NSG mice).
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Expression levels of NAD+ biosynthetic and salvage pathway genes in HLRCC tumors, normal kidney samples and pan-kidney data from TCGA. (A) Overview of NAD+ biosynthetic and salvage pathways. (B-E) Box plots for selected NAD+ biosynthetic genes derived from RNA-seq analysis of HLRCC tumors and normal kidney specimens. (F) Box plots for selected NAD+ biosynthetic genes derived from RNA-seq TCGA pan-kidney data. NAMPT (nicotinamide phosphoribosyltransferase), NAPRT (nicotinate phosphoribosyltransferase ), QPRT (quinolinate phosphoribosyltransferase), NMNAT (nicotinamide mononucleotide adenylyl transferase), KIRP (kidney renal papillary cancer), CIMP (CpG island methylator phenotype), PRCC T1/T2 (papillary renal cell carcinoma type 1/type 2), ccRCC (clear cell renal cell carcinoma), ChRCC (chromophobe renal cell carcinoma).
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Expression levels of NAD+ biosynthetic and salvage pathway genes in HLRCC tumors, normal kidney samples and pan-kidney data from TCGA. (A) Overview of NAD+ biosynthetic and salvage pathways. (B-E) Box plots for selected NAD+ biosynthetic genes derived from RNA-seq analysis of HLRCC tumors and normal kidney specimens. (F) Box plots for selected NAD+ biosynthetic genes derived from RNA-seq TCGA pan-kidney data. NAMPT (nicotinamide phosphoribosyltransferase), NAPRT (nicotinate phosphoribosyltransferase ), QPRT (quinolinate phosphoribosyltransferase), NMNAT (nicotinamide mononucleotide adenylyl transferase), KIRP (kidney renal papillary cancer), CIMP (CpG island methylator phenotype), PRCC T1/T2 (papillary renal cell carcinoma type 1/type 2), ccRCC (clear cell renal cell carcinoma), ChRCC (chromophobe renal cell carcinoma).